Table 4.
Fairness of radiomics survival prediction with different subgroups of age, gender, chemotherapy, HPV status, and lesion size.
| Characteristics | Group | Number (Percentage) | C-Index | p-Value |
|---|---|---|---|---|
| Total (All) | - | 488 (100%) | 0.682 | - |
| Age | 0–50 | 44 (9.0%) | 0.846 | 0.126 |
| 50–60 | 178 (36.5%) | 0.609 | 0.217 | |
| 60–70 | 172 (35.2%) | 0.704 | 0.368 | |
| >70 | 94 (19.3%) | 0.728 | 0.352 | |
| Gender | Male | 402 (82.4%) | 0.663 | 0.325 |
| Female | 86 (17.6%) | 0.759 | 0.147 | |
| Chemotherapy | Yes | 422 (86.5%) | 0.685 | 0.408 |
| No | 66 (13.5%) | 0.555 | 0.022 * | |
| HPV | Yes | 43 (8.81%) | 0.650 | 0.451 |
| No | 274 (56.15%) | 0.551 | 0.006 * | |
| N/A | 171 (35.0) | 0.709 | 0.321 | |
| Tumour size (cm3) | Small = 0–4.03 | 122 (25%) | 0.654 | 0.271 |
| Medium = 4.03–7.70 | 122 (25%) | 0.737 | 0.363 | |
| Large = 7.70–17.3 | 122 (25%) | 0.561 | 0.037 * | |
| Extra Large = 17.3–184.5 | 122 (25%) | 0.633 | 0.378 | |
| Lymph node size (cm3) | Small = 0–2.90 | 122 (25%) | 0.606 | 0.134 |
| Medium = 2.90–11.8 | 122 (25%) | 0.664 | 0.327 | |
| Large = 11.8–24.0 | 122 (25%) | 0.847 | 0.053 | |
| Extra Large = 24.0–124.5 | 122 (25%) | 0.617 | 0.224 |
* shows that there is a statistically significant difference for the subgroup when compared with overall population.